Prevention of breast cancer using selective oestrogen receptor modulators (SERMs) by Powles, Trevor J
Page 1 of 3
(page number not for citation purposes)
Available online http://breast-cancer-research.com/content/8/5/111
Abstract
Placebo controlled trials in over 25,000 women showed that
tamoxifen reduced breast cancer risk by about 40% and osteo-
porotic fracture risk by about 32%. Similarly placebo controlled
trials in nearly 18,000 women showed that raloxifene reduced
breast cancer risk by 44-72% and osteoporotic fractures risk by
30-50%. A direct comparison of tamoxifen with raloxifene showed
similar risk reduction for breast cancer and osteoporotic fractures
with less toxicity for raloxifene.
The results of two very large clinical trials evaluating the
selective oestrogen receptor modulator (SERM) raloxifene for
prevention of breast cancer have been published in the past
few weeks and consolidate our position on the use of these
agents in the prevention of breast cancer.
The first, by Vogel and colleagues [1], reports the results of
the National Surgical Adjuvant Breast and Bowel Project
(NSABP) P2 trial, which directly compares the breast cancer
risk reduction potential of tamoxifen and raloxifene. The
second, by Barrett-Connor and colleagues [2], reports the
results of the Raloxifene Use for the Heart (RUTH) trial, which
compares raloxifene with placebo in women at high risk of
ischaemic heart disease or cardiac events. Breast cancer
incidence was a co-primary outcome in this trial. These trials
follow 20 years of clinical research involving nearly 40,000
women using SERMs to prevent breast cancer.
The first SERM to be evaluated was tamoxifen, which was
tested in four placebo controlled trials started between 1986
and 1992. Over 25,000 healthy women at high risk of breast
cancer were randomised to tamoxifen or placebo for at least
five years. A meta-analysis of these trials in 1993 showed that
tamoxifen reduced breast cancer risk by about 40%, as well
as resulted in a significant reduction in osteoporotic fractures
and serum cholesterol. However, there was significant
toxicity, especially a clinically significant increase in gynaeco-
logical problems, including the need for hysterectomy, uterine
fibroids, endometrial atypia, polyps, and cancer [3]. The
largest of these tamoxifen trials was the NSABP P1 trial,
which randomised 13,388 pre- and postmenopausal women
with an estimated breast cancer risk of >1.66% over 5 years
estimated by the Gail Risk algorithm [4]. The breast cancer
incidence at about 4 years of follow-up showed a very
significant 44% reduction in breast cancer risk [5]. This
provided the basis for approval of tamoxifen by the Food and
Drugs Administration (FDA) for breast cancer risk reduction
in the USA in 1998.
In 1994 another SERM, raloxifene, was evaluated as an anti-
osteoporotic agent in a clinical trial, the Multiple Outcomes
Relevant to Evista (MORE) trial. Subjects in this study were
randomised into three arms, two doses of raloxifene versus
placebo, aimed at determining the effect on the risk of
fracture in 7,700 postmenopausal women with osteoporosis.
At 36 months there was a significant reduction in the risk of
vertebral fractures for both doses of raloxifene (relative risk
(RR) 0.7, 95% confidence interval (CI) 0.5 to 0.8 for
60 mg/day dose; RR 0.5, 95% CI 0.4 to 0.7 for 120 mg/day
dose) but no effect on non-vertebral fracture risk (RR 0.9,
95% CI 0.8 to 1.1) [6]. In this trial breast cancer incidence
was a secondary outcome, and was reduced by 72% at 4
years [7]. With an extension of this trial for a further 4 years
with breast cancer as the primary outcome in the Continuing
Outcomes Relevant to Evista (CORE) trial, analysis at 8 years
confirmed a 66% risk reduction for breast cancer [8]. These
results have now been recently confirmed in another
raloxifene placebo controlled trial, the RUTH trial. This trial
randomised 10,101 postmenopausal women at high risk of
cardiac events to raloxifene 60 mg/day or placebo. After a
median follow up of 5.6 years there was no effect on the
incidence of heart events but there was a significantly
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reduced risk of invasive breast cancer (RR 0.56, 95% CI
0.38 to 0.83) and clinical vertebral fractures (RR 0.65, 95%
CI 0.47 to 0.89) [2]. In these trials there was evidence of an
increase in thromboembolism but no evidence of an increase
in endometrial polyps, atypia or carcinoma.
The results of the raloxifene placebo controlled trials together
with the approval by the FDA of tamoxifen for breast cancer
risk reduction led the NSABP to their P2 trial, which was
designed as a head to head comparison of tamoxifen versus
raloxifene. This started in 1999 and randomised a total of
19,747 postmenopausal women with a Gail risk >1.66% to
raloxifene 60 mg/day or tamoxifen 20 mg/day. The overall
mean Gail score for these women was 4.03 ± 2.17% [1].
The results showed an almost identical incidence of invasive
breast cancer for tamoxifen and raloxifene (RR 1.02, 95% CI
0.82 to 1.28), indicating that both are equally effective at
reducing breast cancer risk. However, for non-invasive breast
cancer the incidence is higher for women on raloxifene than
tamoxifen, indicating a possible lesser risk reduction benefit
for this condition. The toxicity data from this trial confirmed
the previous results of low uterine toxicity for raloxifene, with a
significant reduction in the incidence of endometrial
hyperplasia, atypia and the requirement for hysterectomy. The
incidence of endometrial cancer was less for raloxifene than
tamoxifen (RR 0.62, 95% CI 0.35 to 1.08), in keeping with
the previous indirect comparisons from placebo controlled
trials showing no increase in endometrial cancer risk with
raloxifene. With regard to other toxicities, there were
significantly less thromboembolic events and cataracts with
raloxifene than tamoxifen. There was no difference in the
incidence of ischemic heart disease, stroke, osteoporotic
fractures, other cancers or death.
Overall, the results of these trials show that raloxifene and
tamoxifen are equally effective at reducing the risk of invasive
breast cancer by about 40% and osteoporotic vertebral
fractures by about 35%. However, the toxicity of tamoxifen,
particularly the gynaecological problems, limit its clinical use
for prevention in healthy women. The P2 trial confirms that
raloxifene is less toxic than tamoxifen and, therefore, an
attractive alternative as a risk reduction agent for breast
cancer and vertebral fractures in postmenopausal women.
Which healthy women should be considered for breast
cancer risk reduction? The Gail model is complex and not
generally perceived by women as model for risk assessment,
especially outside the USA. The predominant risk factors that
are recognised as important are a family history of any first
degree relatives and/or a premalignant biopsy (atypia or
lobular carcinoma in situ). Generally, women also recognise
osteoporosis as a potential problem and, therefore, an
increased risk of vertebral fracture because of a previous
fracture, low bone mineral density and/or a family history of
osteoporosis would indicate an added benefit for use of
raloxifene for risk reduction of breast cancer.Some sort of
algorithm or global index is needed so that women and their
doctors can make sensible decisions about the use of
SERMs for breast cancer and osteoporotic fracture risk
reduction. This means that the clinical trials must deal with
the statistical issues concerning multiple outcomes. The
design of treatment trials with one primary outcome balanced
against toxicity is not appropriate for agents like SERMs in a
prevention setting where multiple benefits may ensue and
need to be considered against long term toxicity in healthy
women. It is also important that regulatory authorities have
mechanisms to evaluate these multiple outcomes.
So, where do we go from here? New SERMs are in the
pipeline. Arzoxifene and lasofoxifene are both being evaluated
for multiple outcome benefits, including breast cancer risk
reduction in large clinical trials in healthy women. These will
hopefully build on the success of the clinical trials already
undertaken with tamoxifen and raloxifene. There is no doubt
that SERMs have the potential to prevent breast cancer and
the results from the recent trials with raloxifene offer us
encouragement to achieve this goal.
Conclusion
The SERMs tamoxifen and raloxifene have similar risk
reduction activity for breast cancer and osteoporotic
fractures. Raloxifene has less toxicity, particularly on the
uterus, making it a more attractive option than tamoxifen for
use as a breast cancer risk reduction agent in healthy women.
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